Friday, 15 Dec 2017

You are here

Half of Takayasu's Arteritis Relapse

A French retrospective study of 318 Takayasu's arteritis (TA) patients shows that 50% of patients will relapse and experience a vascular complication ≤10 years from diagnosis. 

A multicenter study examined 318 TA patients meeting both ACR and and Ishikawa criteria to assess event-free survival, relapse-free survival, vascular complications and risk factors for vascular complications.  At diagnosis, TA primarily affects younger (mean age 36 [25–47] years) women (86.8%).

With 6.1 years of follow-up, relapses were observed in 43%, vascular complications in 38%, and death in 5%.

Progressive disease course (P=0.018) and carotidynia (P=0.036) were independently associated with event-free survival.

Outomes observed:

 5 Year10 YearAssociations
Event-Free Survival48.2%36.4%Progressive disease course (P=0.018) and carotidynia (P=0.036)
Relapse-Free Survival58.6%47.7%Male sex (P=0.048), elevated C-reactive protein (P=0.013), and carotidynia (P=0.003)
Complication-Free Survival69.9%53.7%Progressive disease course (P=0.017), thoracic aorta involvement (P=0.009), and retinopathy (P=0.002)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conclusions: This nationwide study shows that 50% of patients with TA will relapse and experience a vascular complication ≤10 years from diagnosis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's

The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.

Fatigue, HAQ and Hand Disability Correlated in Early Systemic Sclerosis

Early diffuse cutaneous systemic sclerosis (SSc) was associated with high levels of disability and fatigue, according to analysis of data from the European Scleroderma Observational Study cohort.

Skin Remission in Dermatomyositis is Uncommon

JAMA Dermatology reports that clinical remission was relatively uncommon in dermatomyositis, despite aggressive systemic therapy, but was best in those receiving mycophenolate during a 3-year study.

Pregnancy Outcomes Worse with Myopathies

Women with the autoimmune inflammatory myopathies dermatomyositis (DM) and polymyositis (PM) are at increased risk for hypertensive disorders in pregnancy, a nationwide retrospective study found.

Health Economics of SLE

A number of presentations over the past few days have addressed the health economics of SLE.